Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD

[lankisterguy]

Advances in Targeted Therapy for R/R CLL

(These OncLive presentations are intended for medical professionals, so reading the provided transcripts and using references to translate the MedSpeak may be required for some patients. See

cllsociety.org/toolbox/abbr...

& cllsociety.org/toolbox/cll-... )

-

EP. #1: Chronic Lymphocytic Leukemia Treatment Landscape

Nicole Lamanna, MD, and Nirav N. Shah, MD, discuss the chronic lymphocytic leukemia treatment (CLL) landscape, including risk factors and treatment options.

onclive.com/view/chronic-ly...

-

EP. #2: Covalent BTK Inhibitors and Common Challenges

Dr Lamanna introduces covalent BTK inhibitors and their use in patients with CLL.

onclive.com/view/covalent-b...

-

EP. #3 Challenges With BTK Inhibitors

Dr Lamanna explains the challenges associated with BTK inhibitors.

onclive.com/view/challenges...

-

EP. #4 Challenges Continued

Nicole Lamanna, MD, continues her discussion on BTK inhibitor challenges.

onclive.com/view/challenges...

-

EP. #5 Non-Covalent BTK Inhibitors

Dr Shah introduces non-covalent BTK inhibitors and clinical findings from their use in the CLL landscape.

onclive.com/view/non-covale...

-

EP. #6 Clinical Implications of BTK Inhibitors in CLL

Dr Shah explains the clinical implications of using BTK inhibitors for CLL treatment.

onclive.com/view/clinical-i...

-

EP. #7 Clinical Implications Continued

Dr Lamanna expands on BTK clinical implications within CLL therapy.

onclive.com/view/clinical-i...

-

EP. #8 BTK Inhibitors and Other B-Cell Malignancies

Two experts discuss the use of BTK inhibitors in the treatment of other B-cell malignancies

onclive.com/view/btk-inhibi...

-

EP. #9 Future Directions for BTK Inhibitors

Nicole Lamanna, MD, and Nirav N. Shah, MD, conclude with their thoughts on the future of BTK inhibitors in CLL.

onclive.com/view/future-dir...

-

Len

[lankisterguy Volunteer]

OncLive Presentation

OncLive Presentation

[cllady01 Former Volunteer]

Thank you!

Some of us older patients (both in length of time with CLL AND in years) still use the transcripts, medical dictionary, and various other props for wading through these most helpful presentations.

In fact the transcripts are most helpful as modulating computer audio is not always successful AND some of our most distinguished UK Drs. have brogues that are difficult to suss out. So many thanks for any transcripts to go along with video presentations.

[JigFettler Volunteer]

Thank you Len. Great links. Jig

[BobbyFour]

Great post, thanks! I love this: “What does this mean for our patients? I think that the most important message that I give a patient who has been newly diagnosed with CLL is that the drugs are so good right now. The goal is to turn CLL into a chronic illness, no different than high blood pressure or diabetes. It does require ongoing management, monitoring for toxicities, surveillance and making sure that the disease is not progressing. I think the hope is that it doesn’t impact your longevity or your quality of life.”

[NaturalWaze in reply to BobbyFour]

Dr Lamanna is my doctor and she tells me that all the time. Of course, I need to hear it all the time!

[BobbyFour in reply to NaturalWaze]

Me too!

[NaturalWaze]

What does the “R/R” stand for? Is that returning CLL after treatment?

[lankisterguy Volunteer in reply to NaturalWaze]

R/R is a MedSpeak acronym for Relapsed/Refractory - meaning the disease / CLL has returned.

Refractory means it is resisting the drug and the disease is coming back during treatment.

Relapsed means the disease came back after stopping the drug. -

Whenever you see odd abbreviations you may want to have this page handy: cllsociety.org/toolbox/abbr...

-

Len

[NaturalWaze in reply to lankisterguy]

Thank you, Len!!

[Fran57]

Thank you Len.Stay safe,

Fran 😷